Clovis Oncology’s great start to June might be getting better, with the Boulder, CO-based biopharmaceutical company announcing late Tuesday it was upsizing its underwritten public offering to $240 million.
Clovis Oncology (NASDAQ: [[ticker:CLVS]]) announced the offering Monday, but set the target amount at $170 million.
Clovis will offer 3,333,334 million shares of common stock at $72 per share, according to a news release from the company.
Clovis shares closed today at $72.10 after opening at $75.77. Clovis has a market cap of $1.9 billion.
The stock took off following Clovis’ announcement June 3 at the American Society of Clinical Oncology that a Phase 1 dose-escalation study of its CO-1686 compound yielded positive results. The compound is being studied as a treatment for non-small cell lung cancer.
Clovis shares were worth $36.58 at the close of trading the day before the announcement.
The offering is expected to close June 17, subject to customary closing conditions. The offering’s underwriters have a 30-day option to purchase up to an additional 486,110 shares of common stock from Clovis to cover over-allotments, if any, the announcement said.
You can read more about Clovis’s sudden surge in this Xconomy article.
